242 related articles for article (PubMed ID: 27697026)
1. Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials.
Kumar B; Kumar R; Skvortsova I; Kumar V
Curr Cancer Drug Targets; 2017; 17(4):357-375. PubMed ID: 27697026
[TBL] [Abstract][Full Text] [Related]
2. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
Sáez-Calvo G; Sharma A; Balaguer FA; Barasoain I; Rodríguez-Salarichs J; Olieric N; Muñoz-Hernández H; Berbís MÁ; Wendeborn S; Peñalva MA; Matesanz R; Canales Á; Prota AE; Jímenez-Barbero J; Andreu JM; Lamberth C; Steinmetz MO; Díaz JF
Cell Chem Biol; 2017 Jun; 24(6):737-750.e6. PubMed ID: 28579361
[TBL] [Abstract][Full Text] [Related]
3. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
4. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Fojo T; Menefee M
Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
[TBL] [Abstract][Full Text] [Related]
6. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
7. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
Jordan MA
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of microtubule stabilization by laulimalide and peloruside A.
Prota AE; Bargsten K; Northcote PT; Marsh M; Altmann KH; Miller JH; Díaz JF; Steinmetz MO
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1621-5. PubMed ID: 24470331
[TBL] [Abstract][Full Text] [Related]
10. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.
Khrapunovich-Baine M; Menon V; Yang CP; Northcote PT; Miller JH; Angeletti RH; Fiser A; Horwitz SB; Xiao H
J Biol Chem; 2011 Apr; 286(13):11765-78. PubMed ID: 21245138
[TBL] [Abstract][Full Text] [Related]
11. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
13. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
[TBL] [Abstract][Full Text] [Related]
14. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
Zúñiga MA; Alderete JB; Jaña GA; Jiménez VA
J Comput Aided Mol Des; 2017 Jul; 31(7):643-652. PubMed ID: 28597356
[TBL] [Abstract][Full Text] [Related]
15. Towards modern anticancer agents that interact with tubulin.
La Regina G; Coluccia A; Naccarato V; Silvestri R
Eur J Pharm Sci; 2019 Apr; 131():58-68. PubMed ID: 30690185
[TBL] [Abstract][Full Text] [Related]
16. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin.
Sharma A; Sáez-Calvo G; Olieric N; de Asís Balaguer F; Barasoain I; Lamberth C; Díaz JF; Steinmetz MO
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640209
[TBL] [Abstract][Full Text] [Related]
17. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
18. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
20. Microtubulin binding sites as target for developing anticancer agents.
Islam MN; Iskander MN
Mini Rev Med Chem; 2004 Dec; 4(10):1077-104. PubMed ID: 15579115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
